Madam Therapeutics initial market is the Urinary tract infection (UTI) market. There is a strong need for novel antibiotic strategies in the UTI market, since it is the most common infection leading to clinic or emergency visits all over the world (>150 million patients). Moreover, there is an ominously rising trend of AMR in urinary pathogens. UTIs are becoming ever harder to treat with common antibiotics leading to serious complications (pyelonephritis, sepsis, or renal abscess).
UTIs are one of the most common types of infections; at least one in two women and one in 10 men will experience a UTI in their lifetime.
Like many human infections, UTIs are usually caused by bacteria living on or in our bodies, and require treatment with antibiotics. What’s alarming the medical community now is that UTIs are becoming ever harder to treat with common antibiotics. We believe that our SAAP platform provides a good alternative to traditional antibiotics that is much more robust to protect against development of resistance.
At some point, most people have taken a course of trimethoprim/sulfamethoxazole (Bactrim) or ciprofloxacin (Cipro), two common antibiotics used for UTIs. However, in the last few years it has become clear that the likelihood these antibiotics will kill most UTIs is dropping rapidly. A frightening New York Times article reported recently that one in three uncomplicated UTIs in young healthy women are Bactrim-resistant and one in five are resistant to five other common antibiotics.
We believe that our SAAP platform provides a good alternative for those women (and men) that suffer from UTI with such “superbugs”